clinical-stage biotech companies

Companies whose enriched business profile is tagged “clinical-stage biotech”, drawn from their SEC filings + website text. Sorted by market capitalization; every figure is delayed data from SEC EDGAR + market data, shown with its as-of date.

• ARCUS BIOSCIENCES INC (RCUS) Health Care — A clinical-stage biopharmaceutical company focused on discovering and developing innovative, small-molecule and antibody-based oncology therapies through a robust pipeline and strategic collaborations. ask →
• ENLIVEN THERAPEUTICS INC (ELVN) Health Care — Enliven Therapeutics is a precision oncology company developing next-generation small molecule inhibitors, led by its clinical-stage BCR-ABL program for chronic myeloid leukemia. ask →
• SELLAS LIFE SCIENCES GROUP INC (SLS) Health Care — SELLAS Life Sciences is a clinical-stage biotech developing novel immunotherapies to address hematologic and solid tumor cancers. ask →
• AVALO THERAPEUTICS INC (AVTX) Health Care — A clinical-stage biotechnology company developing targeted monoclonal antibody therapies for immunology and inflammatory conditions. ask →
• AURA BIOSCIENCES INC (AURA) Health Care — Aura Biosciences is a clinical-stage biotech developing targeted, light-activated virus-like drug conjugates (VDCs) designed to treat ocular cancers while preserving organ function and vision. ask →
• EIKON THERAPEUTICS INC (EIKN) Health Care — Eikon Therapeutics is an oncology-focused biopharmaceutical company advancing a clinical pipeline of novel immune-oncology and DNA damage response candidates discovered through its proprietary research platform. ask →
• ENANTA PHARMACEUTICALS INC (ENTA) Health Care — Enanta Pharmaceuticals is a clinical-stage biotechnology company developing oral, small-molecule therapies for RSV and immunological diseases, supported by ongoing hepatitis C royalty revenues. ask →
• IMMUNEERING CORP CLASS A (IMRX) Health Care — Immuneering is a clinical-stage oncology company developing a new class of Deep Cyclic Inhibitors designed to overcome the limitations of chronic targeted therapies in cancer treatment. ask →
• EVOMMUNE INC (EVMN) Health Care — Evommune is a clinical-stage biotech focused on developing innovative oral and injectable therapies to address unmet needs in chronic inflammatory diseases like atopic dermatitis and migraine. ask →
• MACROGENICS INC (MGNX) Health Care — A clinical-stage biotechnology company leveraging proprietary bispecific DART technology and antibody-drug conjugates to develop novel cancer immunotherapies. ask →
• GREENWICH LIFESCIENCES INC (GLSI) Health Care — Developing a late-stage immunotherapy vaccine (GLSI-100) designed to prevent recurrences in HER2/neu positive breast cancer patients. ask →
• LYELL IMMUNOPHARMA INC (LYEL) Health Care — Lyell Immunopharma is developing next-generation, engineered CAR T-cell therapies designed to provide durable, curative responses in hematologic and solid tumor cancers. ask →
• WHITEHAWK THERAPEUTICS INC (WHWK) Health Care — Clinical-stage oncology company developing a pipeline of next-generation antibody-drug conjugates targeting solid tumors. ask →

Not quite it? Describe exactly what you want →

Data: SEC EDGAR (filings) + market data (fundamentals, delayed daily-close). Figures shown with their as-of date.

Last updated 2026-10-08.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.